

PRESS RELEASE

Embargoed for use 12.01am Wednesday, 1 March 2023

AbbVie celebrates recognition as leader in workplace gender equity

SYDNEY, AUSTRALIA March 1, 2023 – AbbVie (NYSE: ABBV) today marked its Employer of Choice for Gender Equality (EOCGE) citation for the 5th consecutive year. AbbVie is among 129 organisations to have been recognised this year.

The citation is designed to recognise and promote active commitment to achieving gender equality in Australian workplaces. Employers with the citation are set apart from other organisations due to a range of factors including a lower gender pay gap and better paid parental leave policies.

Nathalie McNeil, Vice President and General Manager at AbbVie ANZ said the citation was a reflection of the important work AbbVie does to ensure the workplace is somewhere that everyone is equally valued.

"Inclusion is at the heart of our culture and gender equity is an important part of that. It's fundamental that all employees feel they can thrive regardless of their gender or any other diversity characteristic.

"We have a proud history as trail blazers when it comes to gender equity and the citation is formal recognition of our deep commitment to driving positive change. We are very proud to be recognised as an employer of choice," she said.

AbbVie's gender equity strategy is built on three important pillars:

- Flexibility for all
- Parental leave for all
- Equitable benefits for all

Commenting on the citation, Workplace Gender Equality Agency, Mary Wooldridge said "Leading employers, like AbbVie, have stepped up to the plate by taking action to accelerate change for gender equality in the workplace."

The EOCGE citation was awarded to AbbVie in 2022, extending for a two-year period inclusive of 2023.

About AbbVie



AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.au. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

###

Media: Edwina Elliott +61 439 578 865 edwina.elliott@abbvie.com